[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 967,035
  • Shares Outstanding, K 84,090
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,280 K
  • EBIT $ -48 M
  • EBITDA $ -49 M
  • 60-Month Beta 0.94
  • Price/Sales N/A
  • Price/Cash Flow 96.33
  • Price/Book 4.27

Options Overview Details

View History
  • Implied Volatility 79.64% (-5.50%)
  • Historical Volatility 92.64%
  • IV Percentile 7%
  • IV Rank 2.50%
  • IV High 212.20% on 01/20/26
  • IV Low 76.25% on 01/23/26
  • Expected Move (DTE 29) 1.90 (15.62%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 2,635
  • Volume Avg (30-Day) 3,518
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 31,675
  • Open Int (30-Day) 36,377
  • Expected Range 10.29 to 14.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.17
  • Number of Estimates 2
  • High Estimate $-0.16
  • Low Estimate $-0.17
  • Prior Year $-0.10
  • Growth Rate Est. (year over year) -70.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.42 +6.74%
on 05/19/26
19.70 -38.12%
on 04/22/26
-3.35 (-21.56%)
since 04/20/26
3-Month
11.42 +6.74%
on 05/19/26
19.70 -38.12%
on 04/22/26
-4.38 (-26.43%)
since 02/20/26
52-Week
3.38 +260.65%
on 05/23/25
26.95 -54.77%
on 01/23/26
+8.51 (+231.25%)
since 05/20/25

Most Recent Stories

More News
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team...

CRVS : 12.19 (+6.00%)
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential...

CRVS : 12.19 (+6.00%)
Corvus: Q1 Earnings Snapshot

Corvus: Q1 Earnings Snapshot

CRVS : 12.19 (+6.00%)
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting...

CRVS : 12.19 (+6.00%)
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D.,...

CRVS : 12.19 (+6.00%)
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

Two oral presentations including late-breaker at SID  Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free...

CRVS : 12.19 (+6.00%)
Stock Index Futures Gain on Hopes for U.S.-Iran Deal, Netflix Sinks on Disappointing Guidance

June S&P 500 E-Mini futures (ESM26) are up +0.23%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.20% this morning as investors take on more risk amid mounting speculation that a deal to end the...

NFLX : 88.09 (-1.39%)
AA : 64.14 (+0.33%)
JBHT : 262.88 (+2.48%)
ALLY : 42.62 (+4.33%)
ORCL : 188.16 (+3.69%)
ESM26 : 7,419.25 (-0.44%)
TFC : 48.00 (+2.63%)
FITB : 48.86 (+2.65%)
STT : 154.07 (+2.11%)
CRVS : 12.19 (+6.00%)
RF : 27.53 (+2.57%)
ALB : 170.21 (+0.72%)
Corvus: Q4 Earnings Snapshot

Corvus: Q4 Earnings Snapshot

CRVS : 12.19 (+6.00%)
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated...

CRVS : 12.19 (+6.00%)
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference...

CRVS : 12.19 (+6.00%)

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 13.47
2nd Resistance Point 12.96
1st Resistance Point 12.57
Last Price 12.19
1st Support Level 11.67
2nd Support Level 11.16
3rd Support Level 10.77

See More

52-Week High 26.95
Fibonacci 61.8% 17.95
Fibonacci 50% 15.17
Fibonacci 38.2% 12.38
Last Price 12.19
52-Week Low 3.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.